Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Oct 10;30(Suppl 2):II-4–II-15. doi: 10.1002/clc.20237

Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention

Hector M Medina 1, Deepak L Bhatt 2,✉
PMCID: PMC6653096  PMID: 18228647

Abstract

Periprocedural myonecrosis, as evidenced by elevated creatine kinase–myocardial bound (CK‐MB) levels, occurs in up to 25% of patients undergoing percutaneous coronary intervention (PCI) and has been linked with an increased risk of adverse short‐ and long‐term clinical outcomes. Such myonecrosis arises from three main pathophysiological mechanisms: procedure‐related complications, lesion‐specific characteristics (e.g., large thrombus burden, plaque volume), and patient‐specific characteristics (e.g., genetic predisposition, arterial inflammation). Periprocedural myonecrosis has not been definitively identified as the cause of postprocedural ischemic events, although agents that reduce or prevent thrombosis—including aspirin, thienopyridines, heparin, low‐molecular‐weight heparins, glycoprotein IIb/IIIa inhibitors, and direct thrombin inhibitors—have been shown to reduce the incidence of ischemic outcomes in this population, as have agents that reduce inflammation (aspirin, statins). At the same time, antithrombotic agents are known to increase the risk of bleeding and the use of transfusions, which have likewise been associated with worse outcomes in these patients. Thus, optimal management of patients undergoing PCI represents a balance between minimizing the risk of ischemic outcomes and simultaneously minimizing the risk of major bleeding. It may be that patients who have only minor, untreated postprocedural elevations in CK‐MB level (with no clinical or angiographic signs of ischemia) might have a better prognosis than patients who have normal CK‐MB levels but who suffer major bleeding complications. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: myonecrosis, percutaneous coronary intervention, periprocedural bleeding, acute coronary syndromes, unfractionated heparin, direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors, CK‐MB

Full Text

The Full Text of this article is available as a PDF (433.4 KB).

References

  • 1. Gruntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary‐artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61–68. [DOI] [PubMed] [Google Scholar]
  • 2. Serruys PW, Kutryk MJ, Ong AT: Coronary‐artery stents. N Engl J Med 2006; 354: 483–495. [DOI] [PubMed] [Google Scholar]
  • 3. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction–2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893–1900. [DOI] [PubMed] [Google Scholar]
  • 4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, et al.: ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: E1–E211. [DOI] [PubMed] [Google Scholar]
  • 5. Klein LW, Kramer BL, Howard E, Lesch M: Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non‐Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991; 17: 621–626. [DOI] [PubMed] [Google Scholar]
  • 6. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ: Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996; 131: 1097–1105. [DOI] [PubMed] [Google Scholar]
  • 7. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, et al.: Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241–251. [DOI] [PubMed] [Google Scholar]
  • 8. Bhatt DL, Topol EJ: Does creatinine kinase‐MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005; 112: 906–915; discussion 923. [DOI] [PubMed] [Google Scholar]
  • 9. Jeremias A, Gibson CM: Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005; 142: 786–791. [DOI] [PubMed] [Google Scholar]
  • 10. Kleiman NS: Measuring troponin elevation after percutaneous coronary intervention: ready for prime time? J Am Coll Cardiol 2006; 48: 1771–1773. [DOI] [PubMed] [Google Scholar]
  • 11. Gordis L. (ed.) Epidemiology (3rd ed.) Philadelphia, PA: Saunders /Elsevier; 2004. [Google Scholar]
  • 12. Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, et al.: Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006; 47: 951–961. [DOI] [PubMed] [Google Scholar]
  • 13. Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, et al.: Angiographic adverse events, creatine kinase‐MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE‐2 substudy). Am J Cardiol 2006; 97: 1591–1596. [DOI] [PubMed] [Google Scholar]
  • 14. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, et al.: Long‐term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479–484. [DOI] [PubMed] [Google Scholar]
  • 15. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, et al.: Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention‐related events different? Circulation 2002; 105: 554–556. [DOI] [PubMed] [Google Scholar]
  • 16. Ghazzal Z, Ashfaq S, Morris DC, Douglas JS, Marshall JJ, et al.: Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre‐IIb/IIIa antagonist era. Am Heart J 2003; 145: 1006–1012. [DOI] [PubMed] [Google Scholar]
  • 17. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, et al.: Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461–466. [PubMed] [Google Scholar]
  • 18. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, et al.: Differential impact on survival of electrocardiographic Q‐wave versus enzymatic myocardial infarction after percutaneous intervention: a device‐specific analysis of 7147 patients. Circulation 2001; 104: 642–647. [DOI] [PubMed] [Google Scholar]
  • 19. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, et al.: Creatine kinase‐MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100: 2400–2405. [DOI] [PubMed] [Google Scholar]
  • 20. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ: Association between CK‐MB elevation after percutaneous or surgical revascularization and three‐year mortality. J Am Coll Cardiol 2002; 40: 1961–1967. [DOI] [PubMed] [Google Scholar]
  • 21. Dangas G, Mehran R, Feldman D, Stoyioglou A, Pichard AD, et al.: Postprocedure creatine kinase‐MB elevation and baseline left ventricular dysfunction predict one‐year mortality after percutaneous coronary intervention. Am J Cardiol 2002; 89: 586–589. [DOI] [PubMed] [Google Scholar]
  • 22. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, et al.: Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995; 25: 1693–1699. [DOI] [PubMed] [Google Scholar]
  • 23. Kini A, Marmur JD, Kini S, Dangas G, Cocke TP, et al.: Creatine kinase‐MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low‐to‐medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34: 663–671. [DOI] [PubMed] [Google Scholar]
  • 24. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, et al.: Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT‐II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis‐II. J Am Coll Cardiol 1999; 33: 88–96. [DOI] [PubMed] [Google Scholar]
  • 25. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, et al.: Correlation of postpercutaneous coronary intervention creatine kinase‐MB and troponin I elevation in predicting mid‐term mortality. Am J Cardiol 2004; 93: 18–23. [DOI] [PubMed] [Google Scholar]
  • 26. Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, et al.: Long‐term clinical events following creatine kinase–myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35: 1134–1141. [DOI] [PubMed] [Google Scholar]
  • 27. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, et al.: Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998; 97: 322–331. [DOI] [PubMed] [Google Scholar]
  • 28. Jeremias A, Baim DS, Ho KK, Chauhan M, Carrozza JP Jr, et al.: Differential mortality risk of postprocedural creatine kinase‐MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 2004; 44: 1210–1214. [DOI] [PubMed] [Google Scholar]
  • 29. Kugelmass AD, Cohen DJ, Moscucci M, Piana RN, Senerchia C, et al.: Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994; 74: 748–754. [DOI] [PubMed] [Google Scholar]
  • 30. Cutlip DE, Kuntz RE: Does creatinine kinase‐MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005; 112: 916–922; discussion 922. [PubMed] [Google Scholar]
  • 31. Chew DP, Bhatt DL, Lincoff AM, Wolski K, Topol EJ: Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 2006; 92: 945–950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, et al.: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403. [DOI] [PubMed] [Google Scholar]
  • 33.ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360. [PubMed] [Google Scholar]
  • 34. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, et al.: Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–1375. [DOI] [PubMed] [Google Scholar]
  • 35. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111. [DOI] [PubMed] [Google Scholar]
  • 36.The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830. [PubMed] [Google Scholar]
  • 37. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–2420. [DOI] [PubMed] [Google Scholar]
  • 38. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study. Lancet 2001; 358: 527–533. [DOI] [PubMed] [Google Scholar]
  • 39. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, et al.: A clinical trial comparing three antithrombotic‐drug regimens after coronary‐artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665–1671. [DOI] [PubMed] [Google Scholar]
  • 40. Schomig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, et al.: Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997; 29: 28–34. [DOI] [PubMed] [Google Scholar]
  • 41. Schuhlen H, Hadamitzky M, Walter H, Ulm K, Schomig A: Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz‐Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997; 95: 2015–2021. [DOI] [PubMed] [Google Scholar]
  • 42. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, et al.: Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679–684. [DOI] [PubMed] [Google Scholar]
  • 43. Gum PA, Kottke‐Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–965. [DOI] [PubMed] [Google Scholar]
  • 44. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, et al.: Aspirin‐resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–1655. [DOI] [PubMed] [Google Scholar]
  • 45. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non‐urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122–1126. [DOI] [PubMed] [Google Scholar]
  • 46. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647–654. [DOI] [PubMed] [Google Scholar]
  • 47. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27–33. [DOI] [PubMed] [Google Scholar]
  • 48. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, et al.: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166–e286. [DOI] [PubMed] [Google Scholar]
  • 49.Coronary Interventions Antiplatelet Based Only (CIAO) Trial: Trial Challenges Heparin Use During Low‐Risk PCI, [Transcatheter Cardiovascular Therapeutics (TCT) Web site]. Presented at TCT 2006; October 22–27, 2006; Washington DC, Available at: http://www.tct2006.com/Dailies_TCT2006/tuesday_fulltext/Trial_ Challenges_Heparin_Use_During_Low_risk_PCI.html. Accessed June 21, 2007.
  • 50. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, et al.: Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961–966. [DOI] [PubMed] [Google Scholar]
  • 51. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, et al.: Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994–998. [DOI] [PubMed] [Google Scholar]
  • 52. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low‐molecular‐weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251–256. [DOI] [PubMed] [Google Scholar]
  • 53. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, et al.: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294–299. [DOI] [PubMed] [Google Scholar]
  • 54. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, et al.: Heparin and low‐molecular‐weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(suppl 1): 64S–94S. [DOI] [PubMed] [Google Scholar]
  • 55. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238–244. [DOI] [PubMed] [Google Scholar]
  • 56. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, et al.: A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non‐Q‐Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447–452. [DOI] [PubMed] [Google Scholar]
  • 57. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Q‐wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601. [DOI] [PubMed] [Google Scholar]
  • 58. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, et al.: Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non‐ST‐segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292: 55–64. [DOI] [PubMed] [Google Scholar]
  • 59. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, et al.: Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54. [DOI] [PubMed] [Google Scholar]
  • 60. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, et al.: Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006–1017. [DOI] [PubMed] [Google Scholar]
  • 61. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, et al.: Comparison of low‐molecular‐weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–68. [DOI] [PubMed] [Google Scholar]
  • 62.FRagmin and Fast Revascularisation During InStability in Coronary Artery Disease Investigators: Long‐term low‐molecular‐mass heparin in unstable coronary‐artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–707. [PubMed] [Google Scholar]
  • 63. Lagerqvist B, Husted S, Kontny F, Naslund U, Stahle E, et al.: A long‐term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two‐year follow‐up of the FRISC‐II invasive study. J Am Coll Cardiol 2002; 40: 1902–1914. [DOI] [PubMed] [Google Scholar]
  • 64. Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, et al.: 5‐year outcomes in the FRISC‐II randomised trial of an invasive versus a non‐invasive strategy in non‐ST‐elevation acute coronary syndrome: a follow‐up study. Lancet 2006; 368: 998–1004. [DOI] [PubMed] [Google Scholar]
  • 65. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH: Unstable angina pectoris. N Engl J Med 2000; 342: 101–114. [DOI] [PubMed] [Google Scholar]
  • 66. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta‐analysis of randomized trials. JAMA 2005; 293: 2908–2917. [DOI] [PubMed] [Google Scholar]
  • 67. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, et al.: Utilization of early invasive management strategies for high‐risk patients with non‐ST‐segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–2104. [DOI] [PubMed] [Google Scholar]
  • 68. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887. [DOI] [PubMed] [Google Scholar]
  • 69.The CAPTURE Study: Randomised placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 1429–1435. [PubMed] [Google Scholar]
  • 70. Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, et al.: Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM‐PLUS). Am J Cardiol 2004; 94: 774–776. [DOI] [PubMed] [Google Scholar]
  • 71. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, et al.: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non‐ST‐segment‐elevation acute coronary syndromes. Circulation 2001; 104: 2767–2771. [DOI] [PubMed] [Google Scholar]
  • 72.The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782. [DOI] [PubMed] [Google Scholar]
  • 73.Organisation to Assess Strategies for Ischemic Syndromes (OASIS‐2) Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429–438. [PubMed] [Google Scholar]
  • 74. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333: 757–763. [DOI] [PubMed] [Google Scholar]
  • 75. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ: Bivalirudin versus heparin during coronary angioplasty for unstable angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952–959. [DOI] [PubMed] [Google Scholar]
  • 76. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, et al.: Long‐term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE‐2 randomized trial. JAMA 2004; 292: 696–703. [DOI] [PubMed] [Google Scholar]
  • 77. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, et al.: Safety and efficacy of sirolimus‐ and paclitaxel‐eluting coronary stents. N Engl J Med 2007; 356: 998–1008. [DOI] [PubMed] [Google Scholar]
  • 78. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al.: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–2216. [DOI] [PubMed] [Google Scholar]
  • 79. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307. [DOI] [PubMed] [Google Scholar]
  • 80. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622. [DOI] [PubMed] [Google Scholar]
  • 81. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Anglo‐Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT‐LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158. [DOI] [PubMed] [Google Scholar]
  • 82.The Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383–1389. [PubMed] [Google Scholar]
  • 83.The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357. [DOI] [PubMed] [Google Scholar]
  • 84.A Randomised Placebo‐Controlled Trial: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals. Lancet 2002; 360: 7–22. [DOI] [PubMed] [Google Scholar]
  • 85. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, et al.: High‐dose atorvastatin vs usual‐dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–2445. [DOI] [PubMed] [Google Scholar]
  • 86. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504. [DOI] [PubMed] [Google Scholar]
  • 87. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–1718. [DOI] [PubMed] [Google Scholar]
  • 88. Nissen SE: High‐dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292: 1365–1367. [DOI] [PubMed] [Google Scholar]
  • 89. Topol EJ: Intensive statin therapy–a sea change in cardiovascular prevention. N Engl J Med 2004; 350: 1562–1564. [DOI] [PubMed] [Google Scholar]
  • 90. Gurm HS, Breitbart Y, Vivekanathan D, Yen MH, Fathi R, et al.: Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy–a propensity‐adjusted analysis. Am Heart J 2006; 151(1031): e1031–e1036. [DOI] [PubMed] [Google Scholar]
  • 91. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, et al.: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691–696. [DOI] [PubMed] [Google Scholar]
  • 92. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, et al.: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA‐CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty‐Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48: 1560–1566. [DOI] [PubMed] [Google Scholar]
  • 93. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, et al.: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA‐ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272–1278. [DOI] [PubMed] [Google Scholar]
  • 94. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2004; 110: 674–678. [DOI] [PubMed] [Google Scholar]
  • 95. Patel TN, Shishehbor MH, Bhatt DL: A review of high‐dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007; 28: 664–672. [DOI] [PubMed] [Google Scholar]
  • 96. Abbas AE, Brodie B, Dixon S, Marsalese D, Brewington S, et al.: Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96: 173–176. [DOI] [PubMed] [Google Scholar]
  • 97. Berry C, Kelly J, Cobbe SM, Eteiba H: Comparison of femoral bleeding complications after coronary angiography versus percutaneous coronary intervention. Am J Cardiol 2004; 94: 361–363. [DOI] [PubMed] [Google Scholar]
  • 98. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, et al.: Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44: 547–553. [DOI] [PubMed] [Google Scholar]
  • 99. Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, et al.: Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV‐ACS. Am Heart J 2004; 147: 865–873. [DOI] [PubMed] [Google Scholar]
  • 100. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930–935. [DOI] [PubMed] [Google Scholar]
  • 101. Brown DL: Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003; 89: 535–537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Cote AV, Berger PB, Holmes DR Jr, Scott CG, Bell MR: Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 2001; 76: 890–896. [DOI] [PubMed] [Google Scholar]
  • 103. Jong P, Cohen EA, Batchelor W, Lazzam C, Kreatsoulas C, et al.: Bleeding risks with abciximab after full‐dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001; 141: 218–225. [DOI] [PubMed] [Google Scholar]
  • 104. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, et al.: Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–782. [DOI] [PubMed] [Google Scholar]
  • 105. Braunwald E, Fauci AS, Isselbacher KJ, Kasper DL, Hauser SL, et al. (eds): Harrison's Online. New York: McGraw Hill; 2005. [Google Scholar]
  • 106. Moscucci M, Ricciardi M, Eagle KA, Kline E, Bates ER, et al.: Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions. Am J Cardiol 1998; 81: 702–707. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES